IONS vs ERAS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IONS · Ionis Pharmaceuticals$26.58 ▼ 2.35%
ERAS · Erasca$13.61 ▼ 4.29%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IONS -66.1%
- ERAS +370.9%
Head to head
| Metric | IONS | ERAS |
|---|---|---|
| Price | $26.58 | $13.61 |
| Change today | ▼ 2.35% | ▼ 4.29% |
| Market cap | $4.43B | $4.78B |
| Return, 3 months | -57.2% | -22.7% |
| Return, year to date | -66.4% | +265.9% |
| Return, 1 year | -65.1% | +366.1% |
| P/E (TTM) | – | – |
| P/B | 11.2 | 5.2 |
| P/E percentile vs own 5y | 89th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +54.9% | – |
| Net profit growth (YoY) | +14.5% | -67.7% |
| Gross margin | 98.2% | – |
| Operating margin | -58.8% | – |
| Net margin | -56.9% | – |
| Return on equity | -108.1% | -48.7% |
| Analyst target vs. price | +172.3% | +81.3% |
| Analyst buy share | 95% | 67% |
| RSI (14) | 22 | 43 |
| 30-day volatility | 82.9% | 81.2% |
| Max drawdown, 1 year | -69.3% | -59.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ERAS is the largest of the group by market value.
- ERAS has returned the most over the past year.
- ERAS has been the calmest stock over the last 30 days.